PROM1 and colonic neoplasm: A previous study reported that activation of MEK-ERK1/2 pathway promoted tumorigenicity and metastasis in CD133+ primary colon cancer cells and the clonogenic growth of CD133+ cells was greatly reduced by inhibiting the ERK1/2 activity25.